New hope against a deadly brain infection: large trial tests safer antifungals

NCT ID NCT06666322

Recruiting now Disease control Sponsor: David Boulware Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This large platform trial is testing new antifungal drug combinations for cryptococcal meningitis, a severe brain infection that is fatal without treatment and common in people with HIV. The study will enroll 2,000 participants across multiple sites to compare a newer oral drug, oteseconazole, against standard therapy. The goal is to find treatments that are less toxic, more effective, and easier to access worldwide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Oteseconazole (an oral antifungal drug) compared to standard therapy (liposomal amphotericin B, flucytosine, fluconazole)
What this could lead to: If successful, this could provide safer, more effective, and more accessible treatments for cryptococcal meningitis, potentially lowering the high death rate in low-resource settings.
What could go wrong: This is an early-to-mid-stage platform trial, so results are not guaranteed. New drugs may have unexpected side effects or fail to outperform existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRYPTOCOCCAL MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS Cryptococcal meningitis HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRYPTOCOCCAL MENINGITIS HIV

Contacts and locations

Locations

Infectious Diseases Institute
RECRUITING

Kampala, Uganda
Mbarara University of Science and Technology
RECRUITING

Mbarara, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.